Isconova meet the need of effective adjuvants with an industrially proven high performance novel adjuvant, for the development of successful and innovative vaccines.

The use of ISCOM technology in veterinary vaccine research and development has become more intense. One major factor is the concern relating to the over-use of antibiotics. The pandemic threat together with a growing need of efficient and safe pet vaccines has increased the interest of ISCOM-based adjuvants.

The development of commercial vaccines has further refined AbISCO® adjuvants. The well-tolerated formulation is efficient and safe. With today’s concern about animal welfare, AbISCO® is an excellent choice in antibody production.

Examples of successful ISCOM technology-based vaccine formulations abound in the literature. To date, over 450 publications describe their immunopotentiating properties in terms of antibody responses, cellular responses, cytokine and chemokine production, and protection against infection.